Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo

In the Media

  • September 11, 2018

Laboratory Focus: InMed and UBC Receive Grant From NSERC

InMed Pharmaceuticals Inc., announces that their research partner, the University of British Columbia (UBC), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) for their collaborative efforts with InMed in the biosynthesis of cannabinoids.

NSERC has committed funding of C$136,000 over the course of three years to the research revolving around cannabinoid biosynthesis. The collaboration is called the ‘Microbial metabolic engineering for cannabinoid biosynthesis’, which originally commenced in May 2015, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical needs.

InMed’s vice president, Pre-Clinical Research & Development, Eric Hsu, Ph.D., comments, “We are honored that our trusted, world-class research partner, Dr. Yadav at UBC, has received this prestigious grant from the NSERC.  Through our continued research effort on this program with UBC, we remain optimistic that the development of our proprietary biosynthesis platform technology will result in commercial-scale manufacturing of cannabinoids.”

“We would like to take this opportunity to extend our gratitude to the NSERC for their vote of confidence in our cutting-edge work,” adds Vikramaditya G. Yadav, Ph.D., assistant professor in the Department of Chemical & Biological Engineering.  “The successful completion of this Collaboration will not only advance the Company’s manufacturing capabilities and its R&D pipeline, but also provide immense social and strategic benefit to Canada.”

Full Article
Source: Laboratory Focus

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Media News

Cannabinol 101: The Science of Cannabinol (CBN)

Cannabinol, or CBN for short, is one of the more than 100 rare cannabinoids found in the Cannabis plant. CBN is found in aged Cannabis

Read More
June 8, 2020

InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams

In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to

Read More
May 27, 2020

InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams

In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat

Read More
May 11, 2020
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: